Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 symbols : Tak save search
Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer
Published: 2022-07-11 (Crawled : 13:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.91%
H: 0.35%
C: -0.21%
EXEL | $23.295 1.86% 1.82% 1.9M
|
Health Technology
|
| O: 1.67%
H: 0.0%
C: -5.67%
osmic-313 kidney trial cancer phase 3 nivolumab
Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
Published: 2022-06-30 (Crawled : 01:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.51%
H: 0.0%
C: 0.0%
takhzyro children trial positive results phase 3
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
Published: 2022-04-20 (Crawled : 12:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 1.17%
H: 0.68%
C: 0.27%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 1.06%
H: 1.14%
C: 0.91%
ARCT 4 | $27.93 3.22% 3.11% 310K
|
Health Technology
|
| O: -20.04%
H: 28.04%
C: 21.44%
covid-19 arct-154 vaccine mrna phase 3
Takeda’s TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Children Ages 2 to <12 Years of Age With Hereditary Angioedema (HAE)
Published: 2022-04-12 (Crawled : 12:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.07%
H: 0.47%
C: -0.4%
takhzyro label children phase 3 hereditary angioedema
Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer
Published: 2022-03-14 (Crawled : 01:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.42%
H: 0.48%
C: -0.41%
EXEL | $23.295 1.86% 1.82% 1.9M
|
Health Technology
|
| O: 0.0%
H: 1.21%
C: -1.91%
osmic-312 liver trial cancer phase 3
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma
Published: 2022-01-05 (Crawled : 14:30) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.07%
H: 0.8%
C: -1.67%
EXEL | $23.295 1.86% 1.82% 1.9M
|
Health Technology
|
| O: -0.43%
H: 1.5%
C: -3.43%
ntact-03 renal trial cel phase 3 enroll cell carcinoma
Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY™ (Maribavir) in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)
Published: 2021-12-08 (Crawled : 12:30) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: -0.54%
H: 1.2%
C: 0.73%
trial infection phase 3 infections
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung Cancer
Published: 2021-11-09 (Crawled : 15:15) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: 0.0%
EXEL | $23.295 1.86% 1.82% 1.9M
|
Health Technology
|
| O: -0.69%
H: 0.83%
C: -1.02%
lung cancer cancer phase 3 trial enroll
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
Published: 2021-10-12 (Crawled : 13:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.21%
H: 0.14%
C: -1.05%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.16%
H: 0.11%
C: -1.44%
ARCT 4 | $27.93 3.22% 3.11% 310K
|
Health Technology
|
| O: 4.89%
H: 1.6%
C: -1.84%
vaccine phase 3 approval sars-cov-2
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
Published: 2021-09-22 (Crawled : 12:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: -1.11%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.5%
H: 0.36%
C: -0.86%
ARCT 4 | $27.93 3.22% 3.11% 310K
|
Health Technology
|
| O: 1.81%
H: 2.1%
C: -0.32%
phase 2 vaccine phase 3 approval sars-cov-2
Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO 2021
Published: 2021-09-20 (Crawled : 18:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: -1.22%
H: 0.0%
C: 0.0%
EXEL | $23.295 1.86% 1.82% 1.9M
|
Health Technology
|
| O: -1.64%
H: 1.34%
C: -1.29%
results cancer phase 3 trial
GammaDelta Therapeutics Initiates First-in-Human Phase 1 Trial of GDX012 for the Treatment of Acute Myeloid Leukaemia
Published: 2021-09-15 (Crawled : 13:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.6%
H: 1.01%
C: 0.89%
treatment phase 1 trial phase 2 phase 3 leukemia myeloid leukemia
Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver Cancer
Published: 2021-06-28 (Crawled : 09:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.24%
H: 0.03%
C: -0.47%
EXEL | $23.295 1.86% 1.82% 1.9M
|
Health Technology
|
| O: -13.27%
H: 2.16%
C: -11.28%
cancer phase 3 liver trial
Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021
Published: 2021-06-07 (Crawled : 17:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.06%
H: 1.26%
C: 0.72%
EXEL | $23.295 1.86% 1.82% 1.9M
|
Health Technology
|
| O: -0.36%
H: 0.85%
C: -1.03%
results cancer phase 3 trial
Karyopharm Announces Publication of Health-Related Quality of Life Outcomes from Phase 3 SEAL Study of Selinexor in Advanced Unresectable Dedifferentiated Liposarcoma in Future Oncology
Published: 2021-04-19 (Crawled : 12:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: -0.59%
H: 0.71%
C: -0.12%
KPTI | $1.085 -3.98% -4.15% 1.6M
|
Health Technology
|
| O: -0.41%
H: 0.31%
C: -4.55%
phase 3
Subgroup Analysis from Phase 3 Clinical Trial Supports Efficacy of Maribavir Over Conventional Therapies in Transplant Recipients With Cytomegalovirus Infection (Refractory, With or Without Resistance)
Published: 2021-03-15 (Crawled : 15:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 1.36%
H: 1.12%
C: 0.96%
phase 3 trial therapy injection infections
Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan
Published: 2021-02-26 (Crawled : 14:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.72%
H: 0.5%
C: -0.95%
NVAX | $4.205 3.32% 3.21% 3.6M
|
Health Technology
|
| O: 1.81%
H: 3.52%
C: 2.54%
covid phase 1 vaccine license trial phase 3 phase 2
Takeda’s Maribavir Phase 3 Clinical Trial Met Primary Endpoint of Superiority to Conventional Antiviral Therapy in Transplant Recipients With Refractory, With or Without Resistance, Cytomegalovirus Infection/Disease
Published: 2021-02-12 (Crawled : 12:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: -0.29%
H: 0.74%
C: 0.34%
disease therapy antiviral phase 3 trial injection infections
Moderna Announces First Participant Dosed in Phase 1/2 Study of Moderna COVID-19 Vaccine in Japan Led by Takeda
Published: 2021-01-21 (Crawled : 15:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: -0.97%
H: 0.62%
C: -0.63%
MRNA | News S | $107.87 3.26% 3.16% 2.4M
|
Health Technology
|
| O: 0.11%
H: 9.36%
C: 6.15%
covid vaccine phase 3 phase 1 phase 2
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.